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Simple Summary: Cancer cells alter their metabolism to maintain their high need for energy, produce
enough macromolecules for biosynthesis, and preserve their redox status. The investigation of
cancer cell-specific metabolic alterations has vital importance to identify targets to be exploited for
therapeutic development. The pentose phosphate pathway (PPP) is often highly activated in tumor
cells to maintain redox level, as this pathway takes an important role in reactive oxygen species
detoxification. PPP also yields ribose-5-phosphate, a five-carbon sugar essential for synthesizing
nucleotides necessary for DNA replication and cell proliferation. In this study, we inhibited one of the
key enzymes of this biochemical pathway and observed the main functions of this enzyme in breast
cancer cells. We have demonstrated that inhibition of this enzyme reduces cell proliferation and
leads to cell cycle arrest and apoptosis. Besides that, we showed that the inhibition of this enzyme
causes an alteration in cellular metabolism. All these findings indicate that targeting this enzyme
with specific pharmacological inhibitors is an effective strategy in fighting cancer.
Abstract: The pentose phosphate pathway (PPP) plays an essential role in the metabolism of
breast cancer cells for the management of oxidative stress and the synthesis of nucleotides. 6-
phosphogluconate dehydrogenase (6PGD) is one of the key enzymes of the oxidative branch of
PPP and is involved in nucleotide biosynthesis and redox maintenance status. Here, we aimed to
analyze the functional importance of 6PGD in a breast cancer cell model. Inhibition of 6PGD in MCF7
reduced cell proliferation and showed a significant decrease in glucose consumption and an increase
in glutamine consumption, resulting in an important alteration in the metabolism of these cells. No
difference in reactive oxygen species (ROS) production levels was observed after 6PGD inhibition,
indicating that 6PGD, in contrast to glucose 6-phosphate dehydrogenase, is not involved in redox
balance. We found that 6PGD inhibition also altered the stem cell characteristics and mammosphere
formation capabilities of MCF7 cells, opening new avenues to prevent cancer recurrance after surgery
or chemotherapy. Moreover, inhibition of 6PGD via chemical inhibitor S3 resulted in an induction of
senescence, which, together with the cell cycle arrest and apoptosis induction, might be orchestrated
by p53 activation. Therefore, we postulate 6PGD as a novel therapeutic target to treat breast cancer.
Keywords: breast cancer; pentose phosphate pathway; cancer metabolism; 6PGD
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1. Introduction
Alteration in metabolism is one of the emerging hallmarks of cancer [1]. Many ob-
servations made during the early period of cancer biology research revealed metabolic
changes, such as the Warburg effect [2,3], to be a common feature of cancer cells. Nowa-
days, multiple molecular mechanisms, both intrinsic and extrinsic, are known to play a
vital role in reprogramming cellular metabolism in order to fulfill the three basic needs
for cancer cell survival: (i) maintenance of energy status, (ii) increased biosynthesis of
macromolecules, and (iii) preservation of appropriate redox status. Nevertheless, many
mechanisms regulating metabolic reprogramming are still unknown, and the search for
novel tumor-specific metabolic dependencies exploitable for therapeutic interventions is a
growing field in cancer research.
The pentose phosphate pathway (PPP) plays essential roles not only in nucleotide
biosynthesis and the maintenance of redox status but also in various aspects related to
cancer cells viability, including proliferation, apoptosis, drug resistance, invasiveness,
metastasis, and senescence [4–8]. Moreover, as an alternative pathway to glycolysis for
glucose metabolism, PPP metabolizes from 5 to 30% of glucose depending on the tissue
type [8]. In particular, breast cancer cells are reported to be eight times more dependent
on PPP compared to their non-cancerous counterparts to maintain their redox status [9].
Because of all these crucial aspects, cancer cells are significantly dependent on PPP to
maintain their highly proliferative state [10,11]. Therefore, the therapeutic potential of
targeting PPP has attracted the interest of researchers in the field and both oxidative and
non-oxidative branches of this metabolic pathway have been of keen interest to be used as
a therapeutic drug target [5,10,12,13].
PPP consists of two branches that converge in the production of ribose-5-phosphate,
which is essential for the synthesis of nucleotides (Supplementary Figure S1). The ox-
idative branch of PPP (ox-PPP) is a non-reversible metabolic pathway where glucose-6-
phosphate (G6P) is transformed into 6-phosphoglucono-δ-lactone by glucose-6-phosphate
dehydrogenase (G6PD) and, subsequently, to ribulose-5-phosphate by 6-phosphogluconate
dehydrogenase (6PGD) with the concomitant production of nicotinamide adenine dinu-
cleotide phosphate (NADPH). The resulting ribulose-5-phosphate is then converted to
ribose-5-phosphate and used for biosynthesis of nucleotides. The non-oxidative branch
(nonox-PPP), on the other hand, consists of a set of reversible reactions in which ribose-5-
phosphate and xylulose-5-phosphate are converted to glyceraldehyde-3-phosphate and
fructose-6-phosphate by transketolase (TKT) and transaldolase (TALDO), which are then
utilized for glycolysis [8,14].
The oxidative branch of PPP is of particular interest because it is able to produce
NADPH, and therefore plays a key role in the regulation of reactive oxygen species (ROS)
levels. The balance between ROS production and scavenging has been demonstrated to be
altered in some tumors and has also been proposed to be an attractive therapeutic target on
its own [9,15]. 6PGD, the third enzyme of the ox-PPP, is an excellent target since it plays an
essential role in both the synthesis of nucleotides and generation of NADPH required for
ROS detoxification. Although the importance of 6PGD had till now been overshadowed
by G6PD and TKT [16,17], recent evidence suggests that G6PD alone has only marginal
effects on in vitro proliferation of some particular types of cancer cells, including breast
cancer [6,18,19]. Moreover, new evidence highlighting the potential of 6PGD as a promising
therapeutic target in certain forms of cancer has emerged [6,20–22].
We suggest 6PGD as a better target than G6PD for various reasons. First, despite
the fact that the entire PPP is regulated by several factors, G6PD is much more tightly
controlled through several levels involving transcriptional, translational, post-translational,
and metabolic regulations, being the rate-limiting enzyme of this pathway [23]. Besides, the
NADPH/NADP+ ratio is an important regulator of G6PD, and since up to 75% NADPH
required for de novo lipid synthesis in cellular organisms is produced by G6PD, this enzyme
is also considered as a part of the lipogenic enzyme family, and it is further regulated by
hormone and nutritional factors [20,24]. Therefore, altering the function of G6PD is more
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challenging than other PPP enzymes. On the other hand, inhibition of 6PGD leads to the
accumulation of 6-phosphogluconate (6-PG), a critical glycolysis regulator [24]. Glycolytic
enzyme phosphoglycerate mutase 1 (PGAM1) is reciprocally regulated by 6-PG in a way
that 3-phosphoglycerade (3-PG), the substrate of this enzyme, is also a competitive inhibitor
of 6PGD [24]; therefore, accumulation of 6-PG affects the activity of PGAM1. Besides that,
recent studies reported the direct relationship of 6PGD and the AMP-activated protein
kinase (AMPK) signaling pathway [20,25–28], which further shows the importance of
targeting this enzyme in cancer cells.
In our study, we first characterized the metabolic reprogramming induced by the
knockdown of 6PGD by RNAi-mediated silencing to further explore the potential of this
enzyme as a therapeutic drug target in the MCF7 breast cancer cell line. Then, we used a
chemical selective 6PGD inhibitor, S3 (1-hydroxy-8-methoxy-anthraquinone), to test the
effect of the inhibition of 6PGD on cellular senescence. In addition, we aimed to investigate
the relation between p53 activation and PPP, since p53 has several vital functions in cellular
metabolism, among which are cell cycle regulation, apoptosis induction, regulation of
glycolysis and PPP, and cellular senescence [29–31]. Because of the high reliance of breast
cancer cells on PPP and their dependence on ROS detoxification to manage oxidative stress
and maintain their survival [11,22,32], we targeted 6PGD in MCF7. MCF7 is an estrogen
and progesterone receptor (ER and PR, respectively) positive, and a human epidermal
growth factor receptor 2 (HER2) negative cell line [33]. This cell line is demonstrated
to have more than 4 times higher 6PGD at mRNA, protein, and enzyme activities levels
compared to healthy breast cancer cell lines MCF10A and HMT3522. Besides that, it shows
similar 6PGD levels at mRNA, protein, and specific enzyme activity levels among a panel
of different breast cancer cell lines including MDA-MB-468 and MDA-MB-231 (both triple
negative) and SKBR3 (ER, PR negative, and HER2 positive) [22,33].
2. Materials and Methods
2.1. Cell Culture
Breast cancer cell line MCF7 was purchased from ATCC, and it was cultured in MEM
without phenol red (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) containing 10%
fetal bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 10 mM d-glucose
(Sigma-Aldrich, St. Louis, MO, USA), 1 mM sodium pyruvate (Biological Industries, Beit
HaEmek, Israel), 2 mM glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA),
0.1% antibiotic (penicillin 10 units/mL-streptomycin 10 units/mL, Gibco), 0.01 mg/mL
insulin (Sigma, St. Louis, MO, USA), and 1% non-essential amino acids (Biological Indus-
tries, Beit HaEmek, Israel). Cells were maintained at 37 ◦C with 5% CO2 and saturated
humidity. Growth medium was replaced every 2–3 days, and cells were passed before they
reached 80% confluence.
2.2. siRNA Transfection
For the transfection, MCF7 cells were seeded at a density of 1 × 105 cells per well in
a 6-well plate with an antibiotic-free growth medium. After 24 h, cells were transfected
in triplicates with 50 nM of either siNEG or siRNAs against 6PGD using Metafectene®
Pro (Biontex, München, Germany) according to the manufacturer’s protocol. The medium
was replaced after 6 h with normal medium containing antibiotics. The siRNA sequences
targeting 6PGD were purchased from Dharmacon (Lafayette, CO, USA) and are listed as
follows: si6PGD-1, GAUCAUCUCUUACGCUCAA; si6PGD-2, GAGCAGGCCACUUCGU-
GAA. Non-targeting siRNA (siNEG) was also purchased from Dharmacon (sequence not
provided by the manufacturer).
2.3. RNA Isolation and Gene Expression Analysis
RNA isolation from the transfected cells from fresh or frozen plates was done using
Trizol® reagent (Sigma, MA, USA) according to the manufacturer’s protocol. Conversion of
RNA into cDNA was done using 1 µg of RNA, random primers (Roche, Basel, Switzerland),
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and M-MLV reverse transcriptase enzyme (Invitrogen) according to the manufacturer’s
protocol. Gene expression analysis was performed by RT-PCR (Applied Biosystems®
7500 Real Time PCR) in standard conditions provided by the manufacturer employing
Taqman® (Applied Biosystems, Thermo Fisher Scientific, Darmstadt, Germany) gene-
specific probes for 6PGD. The expression levels were quantified using the ∆∆Ct method
using peptidylprolyl isomerase A (PPIA) as a reference gene.
2.4. Enzyme Activity Assays
Fresh cell culture plates were rinsed with PBS and lysed with lysis buffer (20 mM
tris-HCl, pH 7.5, 1 mM dithiothreitol, 1 mM EDTA, 0.02% (v/v) triton X-100, 0.02% (v/v)
sodium deoxycholate) supplemented with protease and phosphatase inhibitor cocktails
(Thermo Scientific). Cells were scrapped and the cell lysate was disrupted by sonication
using a titanium probe (Vibracell, Sonics & Materials Inc., Tune 50, Output 20, 3 cycles of
5 s each) and centrifuged at 12,000× g at 4 ◦C for 20 min. The supernatant was separated
and immediately used to determine specific enzyme activities of 6-phosphogluconate
dehydrogenase, lactate dehydrogenase, malic enzyme, isocitrate dehydrogenase, and
transketolase using the COBAS Mira Plus analyzer (Horiba ABX, Kyoto, Japan). All
enzymatic activities were determined by monitoring the increase or decrease of absorbance
due to NAD(P)H at 340 nm wavelength (ε 6.23 × 103). The enzyme activity for each sample
was then normalized to the total protein content of the samples measured by BCA assay at
550 nm (Pierce, Thermo Fisher Scientific, Waltham, MA, USA).
2.4.1. 6-Phosphogluconate Dehydrogenase (6PGD), Malic Enzyme (ME) and Isocitrate
Dehydrogenase (IDH)
Specific activities of 6PGD, ME, and IDH were measured by adding samples to a
cuvette containing 0.5 mM NADP+ in 50 mM tris-HCl (including 0.2 mM MgCl2), pH 7.6,
at 37 ◦C. The reaction was initiated by the addition of 6PG, malate or isocitrate, respectively,
up to a final concentration of 2 mM.
2.4.2. Lactate Dehydrogenase
LDH specific activity was measured by adding samples to a cuvette containing 0.2 mM
NADH in 100 mM KH2PO4/K2HPO4, pH 7.4, at 37 ◦C. The reaction was initiated by the
addition of 10 mM pyruvate up to a final concentration of 0.2 mM.
2.4.3. Transketolase
Specific activity of TKT was measured by adding samples to a cuvette containing
5 mM MgCl2, 0.2 U/mL triose phosphate isomerase, 0.2 mM NADH, 0.1 mM thiamine
pyrophosphate in 50 mM tris-HCl, pH 7.6, at 37 ◦C. The reaction was initiated by the
addition of a substrate mixture prepared by dissolving 50 mM ribose-5-phosphate in
50 mM tris-HCl, pH 7.6, in the presence of 0.1 U/mL ribulose-5-phosphate-3-epimerase
and 1.7 mU/mL phosphoriboisomerase.
2.5. Cell Proliferation and Cell Cycle Distribution Analysis
Proliferation kinetics and viability of the transfected cells were measured using flow
cytometry combining direct cell counting and propidium iodide (PI) staining. The analysis
was performed using a Beckman Coulter® Epics® XLTM Flow Cytometer adjusted to
1 × 104 fluorospheres cut-off. Total cell number was registered, allowing discrimination
between dead and alive cells.
For cell cycle analysis, the transfected cells were harvested after 96 h, resuspended
in 200 µL of 1X TBS buffer, fixed and stained with 200 µL of vindelov-PI solution, and
incubated at room temperature for 30 min in the dark. The analysis was performed using a
Beckman Coulter® Epics® XLTM Flow Cytometer with a cut-off at 1 × 104 cells. Cell cycle
distribution analysis was done using FlowJo® software, through which the percentage of
cells in G1, S, and G2 phases was obtained.
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Viability assay was performed by a modification of the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay described by Mosmann et al. [34]. Briefly,
3 × 103 MCF7 cells/well were seeded in 96-well plates for 24 h before exposure with
different concentrations of S3 (Sigma-Aldrich, MA, USA), and serial dilutions of the com-
pound was added to cell medium. DMSO was added to the control to ensure the real
dose response of the tested compound. Cells were incubated at 37 ◦C with 5% CO2 for
72 h. Then, the medium was removed, and 100 µL of filtered MTT in PBS (0.5 mg mL−1)
was added to wells. After 1 h of incubation with MTT, the medium containing MTT was
aspirated, and the formazan product was dissolved in 100 µL of DMSO. Absorbance values
were measured in an ELISA plate reader at 550 nm wavelength and normalized to the
absorbance of cells cultured without compound. The inhibitory concentration values were
determined using GraphPad Prism software.
2.6. Mammosphere Formation Assay (3D Cell Culture)
The capability of MCF7 cells to grow as single-cell colonies in low-attachment condi-
tions was analyzed by mammosphere formation assay. siRNA transfection was performed
as described before, and the cells were trypsinized 24 h after transfection. Then, cells
were reseeded at a density of 7500 cells/well into 24-well ultra-low attachment plates
(Corning Costar, Corning, NY, USA) along with 1.5 mL of complete media supplemented
with 20 ng mL−1 EGF, 20 ng mL−1 bFGF, 10 µg mL−1 heparin, B27 (1:50), and 0.5 µg mL−1
hydrocortisone. The cells were allowed to grow undisturbed for 10 days and then checked
under a microscope for the mammosphere formation. The quantification of mammosphere
formation capability was measured using the MTT assay [34] by adding MTT reagent to
a final concentration of 0.5 mg/mL into each well followed by incubation at 37 ◦C for
2 h. The plates were then scanned using the HP ScanJet G-4010 scanner at a pixel density
of 2400 ppp and analyzed using ImageJ® Software (public domain National Institutes of
Health, USA, http://rsbweb.nih.gov/ij/). Quantification of the mammosphere formation
capability was done by calculating the total surface area occupied by mammospheres with
a size greater than 0.0000785 cm2, corresponding to a spheroid diameter of 0.01 mm.
2.7. Western Blot
Protein extracts were obtained from either fresh or frozen plates 96 h after transfection
using the protocol described for the enzyme activity assays. The protein level in each
sample was quantified using the BCA assay according to the manufacturer’s protocol.
Western blot analysis was carried out using 30 µg of protein, and after electrophoretic
separation, proteins were transferred onto a PVDF membrane. The membranes were then
blocked with 0.5% of non-fat dry milk in 0.1% PBS-Tween, and then incubated with p53
polyclonal (Merck, Millipore, Darmstadt, Germany) antibody followed by exposure to
corresponding horseradish peroxidase-conjugated secondary antibody. Visualization was
carried out on Fujifilm X-ray using chemiluminescence detection.
2.8. Metabolite Production and Consumption Analysis
Glucose consumption rates in the cells were analyzed by measuring the decrease in
the concentration of extracellular glucose in the media at 96 h, compared to the initial
concentration of glucose, with respect to the total cell number at each time point. The
extracellular glucose concentration at a given time point was measured by calculating
the decrease in NAD(P)H concentration caused by the conversion of total glucose by
hexokinase and conversion of resulting glucose-6-phosphate into D-gluconate-6-phosphate
by G6PD. Similarly, the glutamine consumption rate was estimated by measuring the
change in NADH concentration after conversion of extracellular glutamine into glutamate
by glutaminase and the following conversion of glutamate to α-ketoglutarate by glutamate
dehydrogenase. Glutaminase reaction was performed by incubating the media samples
with 125 mU mL−1 glutaminase in 125 mM acetate buffer (pH 5) with soft agitation for
30 min at 37 ◦C. Lactate concentration was determined by measuring the change in NADH
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concentration resulting from the lactate dehydrogenase (LDH) reaction, which was carried
out at 37 ◦C by adding media to a cuvette containing 1.22 mg/mL NAD and 87.7 U/mL
LDH in 0.2M hydrazine 12 mM EDTA buffer, pH 9. All the measurements were done using
a COBAS Mira Plus chemistry analyzer (ABX Diagnostics) and measuring the absorbance
of NAD(P)H at 340 nm.
2.9. Intracellular ROS Level Measurement
Total intracellular ROS levels were determined using flow cytometry and an H2DCFA
probe (Sigma, MA, USA). Cells were incubated with 5 µM H2DCFA in PBS for 30 min.
Afterwards, PBS was replaced with complete growth medium, and cells were incubated for
15 min at 37 ◦C and 5% CO2. Next, cells were trypsinized and resuspended in a solution
containing 50 µM H2DCFA and 20 µg/mL propidium iodide. Internalized probes reacted
with ROS and emitted fluorescence when excited at 492 nm. Emitted fluorescence was
recorded by a flow cytometer (Beckman Coulter® Epics® XLTM) at 520 nm wavelength
with a cutoff range of 1 × 104 cells. For the ROS analysis, only PI-negative cells were taken
into consideration.
2.10. Apoptosis Measurement
The apoptosis measurement was conducted as previously described [35]. In short,
the transfected cells were washed twice with PBS and trypsinized. The cells were then
collected and incubated in 195 µL of 1X binding buffer (10 mM hepes/NaOH, pH 7.4,
140 mM NaCl, 2.5 mM CaCl2) and 5 µL of annexin V (BendersMedSystem, Vienna, Austria)
for 30 min in the dark. Then, 10 µL of 20 µg/mL PI was added to the samples before
analysis, and the percentage of apoptotic cells was measured using the Beckman Coulter®
Epics® XLTM Flow Cytometer with a cutoff range of 1 × 104 cells. Data analysis was
carried using FlowJo® Software.
2.11. Senescence-Associated-β Galactosidase Activity
We used the senescence β-galactosidase staining kit (9860S; Cell Signaling Technolo-
gies, Danvers, Massachusetts, USA) to detect β-galactosidase activity at pH 6.0 following
the manufacturer’s instructions. In brief, cells were fixed for 15 min at room temperature
and then incubated with β-galactosidase staining solution containing X-gal in a dry incu-
bator (without CO2) at 37 ◦C overnight. As the blue color developed, images were taken
using a contrast phase microscope.
2.12. Statistical Analysis
For statistical analysis, parametric unpaired two-tailed independent samples Student’s
t-test (Mann–Whitney U test) was used. In all figures, bars represent the mean of triplicates
± SD. Statistical significance was assumed if a null hypothesis could be rejected when at
least p < 0.05 for a confidence interval of >95%. One asterisk (*) denotes p-value < 0.05, two
asterisks (**) denote p-value < 0.01 and three asterisks (***) denote p-value < 0.001.
3. Results
3.1. 6PGD Was Successfully Inhibited in MCF7 Cells
We tested the functional role of 6PGD in breast cancer using MCF7 cells as a cell
model.Two siRNA sequences targeting different exonic regions of the 6PGD gene were
tested and the knockdown of 6PGD was measured at mRNA level 72 h after transfection.
Both siRNA sequences showed successful knockdown of 6PGD mRNA expression on
MCF7 cells, with a decrease in fold change of around 60% when compared to the cells
transfected with siNEG. Similarly, the reduction of 6PGD activity was observed 96 h
after transfection by measuring specific enzyme activity. Correspondingly, both siRNA
sequences induced a decrease of around 50% of enzyme activity in MCF7 cells (Figure 1).
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6PGD’s activity (less than 50%), which highlights the importance of 6PGD activity in 
breast cancer cell proliferation. This could be explained because 6PGD inhibition entails a 
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phogluconate (6PG), which has been reported to cause a slower proliferation of cells by a 
not yet fully elucidated mechanism [6]. Therefore, a permanent and stronger inhibition of 
6PGD is expected to result in greater reductions of the proliferation kinetics of breast can-
cer cells. 
Figure 1. 6PGD mRNA expression 72 h after transfection with non-targeting siRNA (siNEG) or
siRNAs against 6PGD. Fold change was calculated with respect to siNEG. 6PGD enzyme activity
levels 96 h post-transfecti i s against 6PGD or non-targeting siRNA. Two asterisks
(**) denote p-value < 0.01.
3.2. 6PGD Knockdown Affects Cell Proliferation, Cell Cycle Distribution, and Apoptosis
The effect of 6PGD knockdown on the cell proliferation rate was measured via flow
cytometry, combining direct cell counting and propidium iodide (PI) staining. Then, 96 h
after transfection, 6PGD-knockdown CF7 cells proliferated around 25% less compared to
siNEG-transfected cells (Figure 2A). This result proves that the altered cellular metabolism
due to 6PGD inhibition results in reduction in cell proliferation rates. It is worth noting
that this effect on MCF7 cells’ proliferation rates results from a limited decrease of 6PGD’s
activity (less than 50%), which highlights the importance of 6PGD activity in breast cancer
cell proliferation. This could be explained because 6PGD inhibition entails a decrease in
pentose biosynthesis, which is essential for proliferating cells to synthesize DNA. Besides,
the knockdown of 6PGD will also produce an accumulation of 6-phosphogluconate (6PG),
which has been reported to cause a slower proliferation of cells by a not yet fully elucidated
mechanism [6]. Therefore, a permanent and stronger inhibition of 6PGD is expected to
result in greater reductions of the proliferation kinetics of breast cancer cells.
Since both cell cycle arrest and apoptosis induction can be related to decreased cell
proliferation rates, we decided to see whether 6PGD knockdown had any effect on them.
As it is reported in many studies, cell cycle dysregulation is a hallmark of cancer cells,
and several proteins controlling the phases of cell cycle have been proposed as antitumor
targets [36,37]. To study the effect of 6PGD knockdown on cell cycle distribution, cells
were stained with Vindelov-PI solution after fixation and analyzed by flow cytometry to
quantify their DNA content. The analysis of cell cycle distribution indicated a significant
arrest in S phase 96 h after 6PGD inhibition (Figure 2B). As any alteration in cell cycle may
induce apoptosis [38], we checked whether the arrest in cell cycle induced apoptosis in
our cell line by carrying out apoptosis assays 96 h after inhibiting 6PGD gene expression.
Flow cytometry analysis using annexin V and PI can assess the presence of non-apoptotic
cells (no interaction with either annexin V or PI), early apoptotic cells (interaction with
only annexin-V), and late apoptotic or necrotic cells (interaction with both annexin V and
PI) [35,39]. In our study, the knockdown of 6PGD in MCF7 showed a significant increase in
the number of early apoptotic and late apoptotic and necrotic cells (Figure 2C).
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knockdown cells and cells transfected with siNEG. (B) Cell cycle distribution analysis of MCF-7 
cells after 96 h of siRNA transfection. The percentage of cells in the different cell cycle phases was 
calculated using FlowJo® software. (C) Apoptosis analysis of MCF7 cells after 96 h of siRNA trans-
fection, measured by flow cytometry using annexin V FITC kit, 96 h after transfection. The per-
centage of cells in the different apoptosis phases was calculated using FlowJo® software. (D) West-
ern blot analysis of p53 expression in cells transfected with si6PGD vs. cells transfected with 
siNEG 96 h after transfection. One asterisk (*) denotes p-value < 0.05, two asterisks (**) denote p-
value < 0.01. 
Since both cell cycle arrest and apoptosis induction can be related to decreased cell 
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As it is reported in many studies, cell cycle dysregulation is a hallmark of cancer cells, and 
several proteins controlling the phases of cell cycle have been proposed as antitumor tar-
gets [36,37]. To study the effect of 6PGD knockdown on cell cycle distribution, cells were 
stained with Vindelov-PI solution after fixation and analyzed by flow cytometry to quan-
tify their DNA content. The analysis of cell cycle distribution indicated a significant arrest 
in S phase 96 h after 6PGD inhibition (Figure 2B). As any alteration in cell cycle may in-
duce apoptosis [38], we checked whether the arrest in cell cycle induced apoptosis in our 
cell line by carrying out apoptosis assays 96 h after inhibiting 6PGD gene expression. Flow 
cytometry analysis using annexin V and PI can assess the presence of non-apoptotic cells 
(no interaction with either annexin V or PI), early apoptotic cells (interaction with only 
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the number of early apoptotic and late apoptotic and necrotic cells (Figure 2C). 
3.3. p53 Is Upregulated with 6PGD Knockdown 
The tumor suppressor gene p53 has been proven to have effects on the regulation of 
cell cycle arrest and apoptosis [40]. Considering this, we decided to assess whether the 
inhibition of 6PGD activity could affect p53 expression. Our results showed an increase in 
p53 protein levels after the inhibition of 6PGD gene expression in MCF7 (Figure 2D, Sup-
plementary Figure S2A). MCF7 cells are known to have the wild type p53 gene [41], and 
therefore we hypothesize that p53 overexpression resulting from 6PGD inhibition can 
i re 2. ( ) l c t etr eas re e ts f cell r liferation, 96 h after transfection, for 6PGD-
c lls and ce ls transfected with siNEG. (B) Cell ycle distribution nalysis of MCF-7
ll t i tr sfectio . The percentage of cells in the di ferent cell cycle phases was
calculated using Flo Jo® soft are. (C) Apoptosis analysis of MCF7 cells after 96 h of siRNA transfec-
tion, measured by flow cytometry using annexin V FITC kit, 96 h after transfection. The percentage
of cells in the different apoptosis phases was calculated using FlowJo® software. (D) Western blot
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transfection. One asterisk (*) denotes p-value < 0.05, two asterisks (**) denote p-value < 0.01.
3.3. p53 Is Upregulated with 6PGD Knockdown
The tumor suppressor gene p53 has been proven to have effects on the regulation of
cell cycle arrest and apoptosis [40]. Considering this, we decided to assess whether the
inhibition of 6PGD activity could affect p53 expression. Our results showed an increase
in p53 protein levels after the inhibition of 6PGD gene expression in MCF7 (Figure 2D,
Supplementary Figure S2A). MCF7 cells are known to have the wild type p53 gene [41],
and therefore we hypothesize that p53 overexpression resulting from 6PGD inhibition can
lead to cell cycle arrest and apoptosis induction, slowing down proliferation rates in MCF7
cells. Therefore, these results highlight an interesting connection between 6PGD activity
and p53 expression, although further studies will be needed to elucidate the relationship
between these proteins in a more detailed way.
3.4. NADPH Produced by 6PGD Is Dispensable for ROS Detoxification
The NADPH produced in PPP provides reducing equivalents for protecting the cells
against the toxicity of ROS by regenerating reduced glutathione (GSH) from glutathione
disulfide (GSSH) by means of glutathione reductase [8]. Taking this into account, we
speculated that inhibiting 6PGD, which is involved in NADPH production, might provoke
changes in breast cancer cells’ total ROS levels. However, the measurement of total intra-
cellular ROS using H2DCFA probes in MCF7 cells transfected with i6PGD did not show
any significant changes in he r ROS pr ductio compared to ells transfected ith siNEG
(Figure 3A). This result indicates that 6PGD might not be involved in the m intenanc of
the redox status of these cells or that these cells are able to resort to alternate pathways
to aintain thei required NADPH levels. Nevertheless, our results indicate that the
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antiproliferative activity resulting from 6PGD inhibition is not related to the existence of
an enhanced oxidative stress.
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3.5. 6PGD Inhibition Leads Breast Cancer Cells to Reprogram Their Central Carbon Metabolism
Can er is not o ly a disorder of proliferation but also a metabolic disease. Therefore,
metabolic changes in cancer cells are considered to h ve a vital role in explaining tumor
formation. Analysis of consumpt on and production rates of extracellular glucose and
lactate showed a significant de rease in gluc se consumption 96 h aft r knockdown of
6PGD gene (Figure 3C). Similarly, lactate production was observed to be reduced, but at
a slightly higher rate. Accordingly, Figure 3D shows the glycolytic efficiency decrease of
both cell lines with 6PGD knockdown, calculated as moles of lactate produced per moles of
glucose consumed, as described previously [42,43]. A decreased rate of glucose to lactate
could be due to a shift from glycolysis towards the TCA cycle for the production of energy
and other intermediates needed for bioenergetic reactions and cells’ survival. This result is
concordant with 6PGD knockdown reducing LDH enzyme activity, as shown in Figure 3B.
Glutamine is an abundant and important amino acid that plays a crucial role in en-
ergy generation, redox homeostasis, synthesis of macromolecules, nitrogen metabolism,
and several signaling pathways relevant in cancer cells [44,45]. Therefore, we decided to
measure the effect of 6PGD knockdown over glutamine consumption. Indeed, an altered
glutamine metabolism was observed when cells were subjected to 6PGD knockdown,
since the ratio between glutamine and glucose consumption was higher after 6PGD in-
hibition (Figure 3C,E), implying that 6PGD knockdown increases MCF7 cells’ glutamine
consumption rate. Since we have found 6PGD inhibition to have no noticeable effect on
total ROS levels (Figure 3A), we hypothesized that the increased consumption of glutamine
could be to produce NADPH via the malic enzyme (ME) and isocitrate dehydrogenase
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(IDH) to maintain the reductive capacity of the cells which would have been compromised
after 6PGD inhibition. Glutamine plays a key role in TCA cycle, such as ME and IDH
do, and the fact that 6PGD knockdown increased glutamine consumption together with
specific activities of ME and IDH enzymes in MCF7 cells (Figure 3B) is consistent with our
hypothesis. It has also been reported that MCF7 cells are more dependent on glutamine
than glucose [46], which is also in agreement with our results. (Figure 3E).
3.6. 6PGD Knockdown Reduces the Mammosphere Formation Capacity of Breast Cancer Cells
One of the biggest challenges in the clinical treatment of tumors is cancer recurrence,
a phenomenon occurring due to stem cell-like properties of cancer cells [47]. Therefore,
we decided to check whether targeting 6PGD could be an effective method to disrupt the
acquisition of stem cell-like properties in MCF7 breast cancer cells. The ability to form
single-cell colonies is one of the characteristic features of cancer stem cells (CSCs) [48], so
we determined the effect of 6PGD inhibition over the stem cell characteristics of MCF7 cells
by measuring their mammosphere formation capability. We observed that mammosphere
formation capability of MCF7 decreased around 50% when the cells were transfected with
si6PGD compared to the cells transfected with siNEG (Figure 4). Besides, the size of the
mammospheres was found to be smaller in cells with reduced 6PGD expression compared
to those without 6PGD knockdown (Figure 4A). This indicates that 6PGD has a crucial
role in maintaining the stem cell characteristics of these luminal breast cancer cells. The
fact that inhibition of 6PGD decreases mammosphere formation capability highlights the
potential of 6PGD as a promising therapeutic target.
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To further characterize 6PGD inhibition in MCF7 cells, we tested the effects of a se-
lective small-molecule inhibitor of 6PGD, S3 [20]. We first determined the inhibitory effect 
of this compound on MCF7 cell proliferation (Figure 5A). We observed that around 30 μM 
of S3 was needed to inhibit the 50% (IC50) of the MCF7 cells. Then, we tested several doses 
of S3 lower than the IC50 value and checked the impact on the activity of 6PGD in MCF7 
cells (Figure 5B). Additionally, 20 μM of S3, which is the IC40 value of S3 in MCF7 cells, 
inhibited the activity of 6PGD by around 25%. Further, we speculated that inhibition of 
this enzyme might lead to senescence; thus, we performed an SA-β-gal assay, which is a 
classic and straightforward method to detect signs of senescence. As shown in Figure 5D, 
a significant increase in cells positive for SA-β-gal was found in MCF7 cells treated with 
20 μM of S3. To confirm these results, we subsequently tested for increased protein levels 
of the key senescence effectors p53 and the anti-apoptotic protein B-cell lymphoma 2 
(BCL-2) (Figure 5C, Supplementary Figure S2B,C). As expected, immunoblot analysis con-
firmed the activation of the p53 and BCL2 regulatory pathways with even lower doses of 
S3 treatment. This finding is concordant with the study of Prieur et al. [49]. 
Figure 4. (A) Representative photographs showing the different shape, size, and number of mammo-
spheres in each experimental condition. (B) Mammosphere formation capability of MCF7 cells after
treatment with siNEG or si6PGD. The total mammosphere area for each condition was represented
as a percentage relative to the total mam osphere surface area of siNEG-transfected cells. Three
ast risks (***) denote p-value < 0.001.
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3.7. S3 Is a Specific 6PGD Inhibitor that Induces Senescence in MCF7 Cells
To further characterize 6PGD inhibition in MCF7 cells, we tested the effects of a
selective small-molecule inhibitor of 6PGD, S3 [20]. We first determined the inhibitory
effect of this compound on MCF7 cell proliferation (Figure 5A). We observed that around
30 µM of S3 was needed to inhibit the 50% (IC50) of the MCF7 cells. Then, we tested several
doses of S3 lower than the IC50 value and checked the impact on the activity of 6PGD in
MCF7 cells (Figure 5B). Additionally, 20 µM of S3, which is the IC40 value of S3 in MCF7
cells, inhibited the activity of 6PGD by around 25%. Further, we speculated that inhibition
of this enzyme might lead to senescence; thus, we performed an SA-β-gal assay, which is a
classic and straightforward method to detect signs of senescence. As shown in Figure 5D,
a significant increase in cells positive for SA-β-gal was found in MCF7 cells treated with
20 µM of S3. To confirm these results, we subsequently tested for increased protein levels of
the key senescence effectors p53 and the anti-apoptotic protein B-cell lymphoma 2 (BCL-2)
(Figure 5C, Supplementary Figure S2B,C). As expected, immunoblot analysis confirmed the
activation of the p53 and BCL2 regulatory pathways with even lower doses of S3 treatment.
This finding is concordant with the study of Prieur et al. [49].




Figure 5. (A) Dose response curve of MCF7 cells for selective 6PGD inhibitor S3 after 72 h of treat-
ment of cells with different doses of S3. (B) Relative 6PGD specific enzyme activity levels 24 h post 
treatment with S3. Fold change was quantified relative to control. (C) Western blot analysis of p53 
and BCL2 expression in cells treated with different doses of S3 or control for 72 h. (D) Representa-
tive photographs showing increased SA-β-gal positive cells in MCF7 cells treated with 20 μM of S3 
compared to cells treated with DMSO alone. In addition, 12.5 μM etoposide was used as a positive 
control as it is known to induce senescence. Three asterisks (***) denote p-value < 0.001. 
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Here, we have first demonstrated that 6PGD has a pivotal role in the proliferation of 
MCF7 cells. The high dependency of these cells to 6PGD is evident, considering that par-
tial inhibition of this enzyme activity (around 50%) led to about 25% decrease in cell pro-
liferation for MCF7 cells. This finding is in line with a previously reported study carried 
out by Yang et al. [22]. Several scenarios might be considered in the reduction of breast 
cancer cells proliferation when 6PGD is impaired. First, decreased nucleotide and 
NADPH synthesis with inhibition of PPP leads to a decrease in cell proliferation since 
nucleotides are needed for the biosynthesis of genetic material, and NADPH is required 
for redox balance and lipid biosynthesis. Besides the increase of glycolysis metabolites, 
6PGD inhibition also results in the accumulation of 6-phosphogluconate and 6-phos-
phogluconolactone, which in turn alters the proliferation of cells [25]. Even though the 
exact mechanism of action of 6PGD is not totally elucidated, its importance in cell prolif-
eration has been reported in several studies [6,20,26,28,52] and a permanent and stronger 
knockdown of this gene using shRNA, CRISPR/Cas technology, or small molecules selec-
tively targeting this enzyme is expected to result in even more significant reductions of 
the proliferation kinetics of the breast cancer cells. 
Furthermore, the cell cycle was also altered in 6PGD inhibited breast cancer cells. An 
expected arrest at the S phase was observed since nucleotide synthesis is partly impaired. 
Similarly, 6PGD knockdown also induced apoptosis in breast cancer cells. This induction 
is visible at both the early and late apoptosis/necrosis level. On the other hand, we showed 
that p53 is augmented on the cells with 6PGD inhibited, which confirms our hypothesis 
that 6PGD knockdown decreases proliferation of breast cancer cells through p53. Consid-
ering that p53 has essential roles in modulation of cell cycle and apoptosis [40] and also 
Figure 5. (A) Dose response curve of MCF7 cells for selective 6PGD inhibitor S3 after 72 h of treatment of cells with different
doses of S3. (B) Relative 6PGD specific enzyme activity levels 24 h post treatment with S3. Fold change was quantified
relative to control. (C) Western blot analysis of p53 and BCL2 expression in cells treated with different doses of S3 or control
for 72 h. (D) Representative photographs showing increased SA-β-gal positive cells in MCF7 cells treated with 20 µM of S3
compared to cells treated with DMSO alone. In addition, 12.5 µM etoposide was used as a positive control as it is known to
induce senescence. Three a terisks (***) denote p-value < 0.001.
4. Discussion
Our study reveals 6PGD as a key enzyme for MCF7 breast cancer cells with an
important metabolic role that is regulated by the p53 tumor suppressor. Several previous
studies have highlighted the importance of PPP in breast cancer tumors, especially those
in advanced states, such as MCF7 [48,50,51]. Therefore, we focused our attention on
investigating the role of the 6PGD, a less studied dehydrogenase enzyme in ox-PPP.
Here, we have first demonstrated that 6PGD has a pivotal role in the proliferation
of MCF7 cells. The high dependency of these cells to 6PGD is evident, considering that
partial inhibition of this enzyme activity (around 50%) led to about 25% decrease in cell
proliferation for MCF7 cells. This finding is in line with a previously reported study carried
out by Yang et al. [22]. Several scenarios might be considered in the reduction of breast
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cancer cells proliferation when 6PGD is impaired. First, decreased nucleotide and NADPH
synthesis with inhibition of PPP leads to a decrease in cell proliferation since nucleotides are
needed for the biosynthesis of genetic material, and NADPH is required for redox balance
and lipid biosynthesis. Besides the increase of glycolysis metabolites, 6PGD inhibition also
results in the accumulation of 6-phosphogluconate and 6-phosphogluconolactone, which
in turn alters the proliferation of cells [25]. Even though the exact mechanism of action
of 6PGD is not totally elucidated, its importance in cell proliferation has been reported in
several studies [6,20,26,28,52] and a permanent and stronger knockdown of this gene using
shRNA, CRISPR/Cas technology, or small molecules selectively targeting this enzyme is
expected to result in even more significant reductions of the proliferation kinetics of the
breast cancer cells.
Furthermore, the cell cycle was also altered in 6PGD inhibited breast cancer cells. An
expected arrest at the S phase was observed since nucleotide synthesis is partly impaired.
Similarly, 6PGD knockdown also induced apoptosis in breast cancer cells. This induction is
visible at both the early and late apoptosis/necrosis level. On the other hand, we showed
that p53 is augmented on the cells with 6PGD inhibited, which confirms our hypothesis that
6PGD knockdown decreases proliferation of breast cancer cells through p53. Considering
that p53 has essential roles in modulation of cell cycle and apoptosis [40] and also knowing
that MCF7 cells have wild type p53 [41], the increase in p53 levels resulting from 6PGD
inhibition led MCF7 cells to alter cell cycle progression with an arrest in the S phase.
Thus, we can conclude that p53 regulates PPP enzymes, including 6PGD. Knowing that
AMP-activated protein kinase (AMPK) couples p53 in cell fate decision [53] and that 6PGD
ablation alters the AMPK levels in breast cancer cells [22], we can conclude that increase in
p53 levels upon inhibition of 6PGD in our experimental design might occur through an
AMPK dependent manner.
Next, we observed that 6PGD knockdown did not change the total intracellular
ROS level of MCF7 cells. Filosa et al. previously demonstrated that G6PD-knockdown
mouse embryonic fibroblasts made use of another source of NADPH production to rescue
ROS [54]. We assume that MCF7 with 6PGD inhibition also recover the missing NADPH
for redox detoxification from other sources such as glutaminolysis and that the decreased
proliferation rate with inhibited 6PGD has an oxidative stress independent mechanism. It
has been demonstrated that the G6PD enzyme does not have a strong effect on cellular
proliferation but is crucial for defense against oxidative stress [55]; nonetheless, our findings
prove the importance of functional 6PGD activity for cell survival in contrast to G6PD
activity. On the other hand, Sukhatme et al. showed that 6PGD inhibition increased G6PD
activity considerably in lung cancer cells [6]. Even though in our cells, 6PGD knockdown
did not cause a strong G6PD activity enhancement, knowing that breast cancer cells have a
very active PPP and that especially MCF7 cells have very high G6PD levels, we assume
that NADPH produced by G6PD together with enhanced glutaminolysis is enough to
compensate the decrease of NADPH resulting from the reduced 6PGD activity as well as
to maintain ROS levels.
To have a complete idea about the effect of 6PGD reduction in breast cancer, we
assessed some flux measurements related to glucose and glutamine metabolism. Like
previously reported studies [6], we also observed a decrease in the glycolytic efficiency after
6PGD inhibition. In addition, the reduction in LDH activity suggests that 6PGD inhibition
causes a shift from glycolysis to TCA cycle. On the other hand, 6-PG accumulation has
been reported to activate glycolytic enzymes PFK and PK in hepatic cells to carry the excess
glucose away from PPP to produce pyruvate for lipid biosynthesis [56,57]. Nevertheless,
we observed reduced glucose consumption in MCF7 cells with 6PGD inhibition, which
might be due to the fact that glucose metabolism in malignant cells is distinct from that of
non-transformed cells.
This study uncovers a link between PPP and glutaminolysis since cells with reduced
6PGD activity consumed more glutamine than control cells. Additionally, the ratio of
glutamine consumption rate over glucose consumption rate was significantly increased. As
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we discussed before, increased glutamine metabolism must be taking place to compensate
for both the missing NADPH and nucleotides caused by 6PGD inhibition. Our results
also reveal that inhibiting 6PGD entails the upregulation of ME and IDH, which probably
constitutes an adaptive mechanism that breast cancer cells undergo to produce NADPH
when the ox- PPP has been blocked. Interestingly, this fact reveals an alternative metabolic
vulnerability that could be targeted to hamper breast cancer cells’ adaptation to 6PGD
inhibition. The simultaneous inhibition of 6PGD and ME or IDH represents a promising
strategy to deprive tumor cells of their ability to compensate for the oxidative stress
through NADPH production. In fact, a recent publication showed that even though 6PGD
enzymatic activity is not indispensable, the inhibition of 6PGD together with any enzyme of
non-oxidative PPP (transketolase, transaldolase, ribulose epimerase, or ribulose isomerase)
is highly detrimental [58]. That is, targeting other metabolic targets along with 6PGD could
result in the development of better therapies against breast cancer cells [59,60].
One of the most striking findings in this study is the uncovered link between PPP
and cancer stem cell characteristics. The results provided in this research clearly show that
6PGD inhibition significantly decreased not only the mammosphere formation capability
but also the size and number of formed mammospheres. To the best of our knowledge,
this is the first study to reveal that an enzyme of the oxidative phase of PPP has significant
effect on diminishing the stem cell-like characteristics of breast cancer cells. This could be
efficient in preventing breast cancer growth and helpful in addressing the severe problem
of cancer recurrence, which is one of the most challenging issues faced by many of the
currently targeted therapies. The fact that the inhibition of 6PGD decreases mammosphere
formation capability highlights the potential of 6PGD as a promising drug target, and
targeting 6PGD could also sensitize cells to current chemotherapeutics, thus improving the
efficacy of the most used clinical approaches [61].
Cancer cells are characterized inherently by a dynamic interplay between proliferation,
cell death, and/or senescence [62]. Previously, it has been reported that knockdown of
6PGD induces cellular senescence in several cancer types including lung tumors [6]. In
accordance with this, our results indicated an increase of SA-β-gal activity in 6PGD-
inhibited MCF7 cells. Besides SA-β-gal activity, senescent cells are known to up-regulate
p53 [49]. Here, we demonstrated the activation of the p53 following S3 treatment. Similar to
apoptosis, senescence also gives opportunities for therapeutic targeting in cancer. The cell
fate choice between senescence and apoptosis can be manipulated by targeting upstream
mediators of apoptosis, such as the anti-apoptotic Bcl-2 family proteins [63]. Here, we also
showed an increased expression of BCL-2 upon S3 treatment in MCF7 breast cancer cells.
Besides our results, a recent study indicated that 6PGD played an important role in
the migration of tumor cells in vitro [64]. Results obtained through cell culture might differ
from true tumors, as cell culture lines have sustained changes in metabolism that may
deviate from the metabolism of native tumors. However, cancer cell lines play a pivotal
role in modern cancer research as preclinical model system since they retain most of the
genetic properties of the cancer of origin under the right conditions and with appropriate
controls. They also have peculiar capability to provide an indefinite source of biological
material for gaining mechanistic and therapeutic insight [65]. Therefore, validation of
this proof of concept in vivo through xenograft experiments will have to be conducted to
further assess the potential of 6PGD inhibition as a therapeutic strategy in breast cancer
treatment, as our results highlight the potential of this new approach.
5. Conclusions
The experimental evidence presented in this work highlights the potential of 6PGD
as a putative therapeutic drug target in breast cancer treatment. Targeting 6PGD not
only reduces cell proliferation through cell cycle arrest and apoptosis induction but also
activates p53 and decreases the stem cell-like characteristics of breast cancer cells. This
could be efficient in preventing breast cancer growth and be helpful in addressing the severe
problem of cancer recurrence, which is one of the most challenging issues faced by current
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targeted therapies. In this sense, targeting 6PGD could also sensitize the cells to current
chemotherapeutics, thus improving the efficacy of the most used clinical approaches [61].
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